There is not enough information on the new "Vietnam variant" of the coronavirus to tell if it is circulating here, Singapore's director of medical services said yesterday.. Read more at straitstimes.com.
Sunday, May 02, 2021, 13:12 GMT+7
Vietnam’s Deputy Minister of Health Tran Van Thuan stands in front of a quarantine zone in Yen Bai Province, where the country’s first-ever case of the Indian coronavirus variant was logged on April 18, 2021. Photo: Ministry of Health
The Indian variant of the novel coronavirus has been detected for the first time in Vietnam after a hotel employee was found having contact with experts from India before being confirmed as a COVID-19 patient last month.
Four Indian experts carried the B.1.617.2 mutant strain, which has been raging in India for the past several weeks, when they were quarantined at a hotel in northern Yen Bai Province, according to genome sequencing at Vietnam’s National Institute of Hygiene and Epidemiology, which was announced by the Ministry of Health on Friday.
Sunday, March 14, 2021, 10:08 GMT+7
A health worker receives a shot of AstraZeneca’s COVID-19 vaccine in Vietnam. Photo: Tuoi Tre
While 26 percent of recipients of AstraZeneca’s COVID-19 vaccine in Vietnam have exhibited mild to severe local reactions, a health official reassured the reaction rates observed so far are “equivalent” to those in other types of inoculation.
COVID-19 vaccination in Vietnam began on Monday, and by Friday about 5,300 people in 12 provinces and cities had received their first jab of the AstraZeneca vaccine.
Among them, 26 percent exhibited local reactions, according to the country’s Preventive Medicine Department (PMD) vice-director Nguyen Minh Hang.
CNA file photo
Taipei, Dec. 16 (CNA) Taiwan s Medigen Vaccine Biologics Corp. (MVC) has applied to begin phase 2 testing of its COVID-19 vaccine, becoming the third local developer seeking permission to test the efficacy of its product on a larger scale, the company said Tuesday.
In a statement, Medigen said all participants in its phase 1 trial had completed the two-dose regimen of the vaccine, allowing researchers to obtain data on its safety and ability to elicit an immune response.
The company said it had applied with Taiwan s Food and Drug Administration (FDA) for permission to begin phase 2 clinical trials to test the vaccine s efficacy on 3,700 volunteers.